Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans - CMPS News | RalliesCompass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans
C
CMPS• COMP360 development and FDA filing progress
- Compass Pathways outlined plans to file a rolling NDA for COMP360 psilocybin in treatment-resistant depression, targeting completion in Q4 2026.
- U.S. launch targeted for H1 2027, contingent on FDA clearance; Breakthrough Therapy designation cited alongside a Priority Review Voucher in TRD.
- Two Phase 3 trials, COMP005 and COMP006, met the primary endpoint on MADRS change at Week 6 with P<0.001.
Durability results and commercial rollout planning
- The company highlighted durability through 26 weeks with infrequent dosing; additional dosing was described as deepening response in some patients.
- Commercial rollout planning centers on certified treatment sites, REMS readiness, specialty pharmacy or buy-and-bill distribution, and payer engagement.
DEA
•
